Product Image

Contributor Information

  • Name Gillian Tozer
  • Institute University of Sheffield

Tool Details

  • Tool name: Mouse fibrosarcoma Luciferase2 mStrawberry VEGF164 Cell Line
  • Alternate names: VEGF-A, VEGF12, VEGF164, VEGF188
  • Tool type: Cell Lines
  • Tool sub-type: Continuous
  • Parental cell line: MEF
  • Organism: Mouse
  • Tissue: Embryo
  • Disease: Cancer
  • Description: Mouse fibrosarcoma cell lines that are capable of expressing all vascular endothelial growth factor (VEGF) isoforms (control) or only single isoforms of VEGF (VEGF120, VEGF164, or VEGF188) were developed under endogenous VEGF promoter control. The original rationale for the development of these cell lines relates to the fact that tubulin-binding vascular-disrupting agents (VDA) are currently in clinical trials for cancer therapy but the factors that influence tumour susceptibility to these agents are poorly understood. Researchers evaluated the consequences of modifying tumour vascular morphology and function on vascular and therapeutic response to combretastatin-A4 3-O-phosphate (CA-4-P), which was chosen as a model VDA. The cell lines themselves could be potentially valuable for the commercial/pharmaceutical industry.
  • Research area: Cancer ; Cell Signaling & Signal Transduction ; Developmental Biology ; Drug Discovery & Development ; Metabolism

  • For Research Use Only

Target Details

Application Details

Handling

  • Format: Frozen
  • Growth medium: High glucose DMEM (Invitrogen) medium, L-glutamine, FCS, G-418 and puromycin. antibiotics G-418 and puromycin
  • Shipping conditions: Dry ice

Documentation

  • Available on request

References

  •   Differential Expression of VEGFA Isoforms Regulates Metastasis and Response to Anti-VEGFA Therapy in Sarcoma. English et al. 2017. Cancer Res. 77(10):2633-2646. PMID: 28377452.
  •   Differential Expression of VEGFA Isoforms Regulates Metastasis and Response to Anti-VEGFA Therapy in Sarcoma.